We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Understanding Cancer Immunoediting Will Aid Vaccine Development

By LabMedica International staff writers
Posted on 29 Feb 2012
The body’s immune system employs the process of cancer immunoediting to eliminate tumor cells bearing highly antigenic mutant proteins and to suppress growth of those cancer cells that lack these antigens.

Cancer immunoediting, the process by which the immune system controls tumor outgrowth and shapes tumor immunogenicity, is comprised of three phases: elimination, equilibrium, and escape. More...
Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. To understand better the molecular basis that drives immunoediting, investigators at Washington University School of Medicine (St. Louis, MO, USA) induced the formation of sarcomas in a line of immunocompromised mice.

The investigators then used massive parallel DNA sequencing to characterize mutations expressed on the sarcoma cells, which were phenotypically similar to unedited primary tumors growing in immunocompetent hosts.

Results published in the February 16, 2012, issue of the journal Nature revealed that the genome of the sarcoma cells contained 3,743 mutations. Using class I prediction algorithms, they identified the protein produced by the mutant spectrin-beta2 gene as a potential rejection antigen of the sarcoma and validated this prediction by conventional antigen expression cloning and detection. They also demonstrated that cancer immunoediting occurred via a T-cell-dependent immunoselection process that promoted outgrowth of preexisting tumor cell clones lacking highly antigenic mutant spectrin-beta2 and other potential strong antigens.

“The idea would be to make a vaccine that helps the immune system recognize and attack six or seven of these mutated proteins in a cancer,” said senior author Dr. Robert Schreiber, professor of pathology and immunology at Washington University School of Medicine. “Therapeutically, that could be very helpful.”

“Many of the cancer genome projects now under way are looking for the “driver” mutations, or the mutations that cause the cancers,” said Dr. Schreiber. “Our results suggest there may be additional information in the sequencing data that can help us make the immune system attack cancers. Until very recently, this work would have been impractical because of the costs involved, but the technology has improved and prices have come down, and now it is possible to obtain this genetic information for a few thousand dollars instead of a million.”

Related Links:

Washington University School of Medicine



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Pathology

view channel
Image: Virtual staining of label-free tissue in imaging mass spectrometry (Photo courtesy of Ozcan Lab/UCLA)

Deep Learning Advances Imaging Mass Spectrometry with Virtual Histological Detail

Imaging mass spectrometry (IMS) is a powerful technique that can map thousands of molecular species in biological tissues with exceptional chemical specificity. However, IMS is hindered by relatively low... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.